The global CAR T-cell therapy market was valued at $1.7 billion in 2022, and is projected to reach $6.1 billion by 2030, growing at a CAGR of 13.5% from 2022 to 2030. The global CAR T-cell therapy market refers to the market for chimeric antigen receptor (CAR) T-cell therapies, which are a type of immunotherapy that involves modifying a patient's T-cells to target and destroy cancer cells. CAR T-cell therapy is a promising new approach to treating certain types of cancer, and it has shown great potential in clinical trials.

The global CAR T-cell therapy market is expected to grow significantly in the coming years, driven by the increasing prevalence of cancer worldwide and the growing demand for new and innovative cancer treatments. 

The market is being driven by several factors, including the increasing number of clinical trials exploring the use of CAR T-cell therapies, the growing number of cancer patients, and the rising investments in research and development by biotechnology and pharmaceutical companies. Additionally, the FDA approvals of CAR T-cell therapies, including Kymriah and Yescarta, have paved the way for the development of new therapies and expanded the market.

However, the high cost of CAR T-cell therapies, the complexity of the treatment, and the potential for serious side effects are some of the factors that could limit the growth of the market. Nonetheless, the CAR T-cell therapy market is expected to continue to grow as new therapies are developed and more patients have access to this promising treatment.

Market Dynamics

Latest Trends

There are several driving factors behind the growth of the global CAR T-cell therapy market:

Increasing prevalence of cancer: The global incidence of cancer is increasing, and this is one of the main driving factors behind the growth of the CAR T-cell therapy market. As the incidence of cancer continues to rise, there is a growing need for new and innovative treatments that can effectively treat the disease.

Partnerships and collaborations: Biotechnology and pharmaceutical companies are forming partnerships and collaborations to develop and commercialize CAR T-cell therapies. These partnerships are expected to accelerate the development and commercialization of new therapies and drive the growth of the market.

Restraining factors

There are also several restraining factors that may limit the growth of the global CAR T-cell therapy market:

High cost: CAR T-cell therapy is a highly complex and expensive treatment, and the high cost of treatment is one of the main limiting factors for patients and healthcare providers. The cost of CAR T-cell therapy is a significant barrier to access for many patients, especially in developing countries.

Regulatory challenges: The regulatory approval process for CAR T-cell therapy is complex and time-consuming. This could limit the development and commercialization of new therapies and slow the growth of the market.

Opportunity Analysis

The global CAR T-cell therapy market presents several opportunities for growth and development. Some of the key opportunities include:

Development of new therapies: The CAR T-cell therapy market is still in its early stages, and there is significant potential for the development of new therapies. Biotechnology and pharmaceutical companies are investing heavily in research and development, and as more therapies become available, the market is expected to grow.

Increasing regulatory approvals: The FDA has already approved two CAR T-cell therapies, and there is potential for the approval of additional therapies in the future. As more therapies receive regulatory approval, the market is expected to grow.

Challenges

There are opportunities for growth and development in the global CAR T-cell therapy market, there are also several challenges that need to be addressed. Some of the key challenges include:

High cost: CAR T-cell therapy is a complex and expensive treatment, which limits its availability and accessibility to patients. The high cost of the treatment can also be a limiting factor for healthcare providers and insurance companies.

Limited availability: Currently, only a few centers worldwide are equipped to provide CAR T-cell therapy. This limited availability of the treatment can be a barrier to access for many patients, especially in developing countries.

Safety concerns: CAR T-cell therapy can cause serious side effects, including cytokine release syndrome (CRS) and neurotoxicity. These safety concerns can limit the use of CAR T-cell therapy and slow the growth of the market.

Competition from alternative treatments: There are alternative treatments available for many types of cancer, including chemotherapy, radiation therapy, and targeted therapy. The availability of these alternative treatments could limit the demand for CAR T-cell therapy.

Segmentation Analysis

Indication Outlook

ALL is the primary indication for CAR T-cell therapy, and it is expected to continue to dominate the market in the coming years. The high prevalence of ALL and the increasing adoption of CAR T-cell therapy as a standard treatment for the disease are the major factors driving the growth of the market.

There are ongoing clinical trials investigating the use of CAR T-cell therapy in other types of cancer, including multiple myeloma, solid tumors, and glioblastoma. The successful development of CAR T-cell therapy for these indications could significantly expand the indication outlook segment of the global CAR T-cell therapy market.

The indication outlook segment of the global CAR T-cell therapy market is currently dominated by ALL, DLBCL, and MCL. However, there are ongoing clinical trials investigating the use of CAR T-cell therapy in other types of cancer, which could lead to the expansion of the market. The growth of the market in each indication is driven by various factors, including the prevalence of the disease, the availability of CAR T-cell therapy, and the development of new therapies.

Drug Type Outlook

Autologous CAR T-cell therapy involves the collection of a patient's own T-cells, which are then genetically modified to express a chimeric antigen receptor (CAR) and infused back into the patient. This type of CAR T-cell therapy is the most widely used and is expected to dominate the market in the near term.

Switchable CAR T-cell therapy involves the use of a CAR T-cell therapy that can be turned on and off by the administration of a small molecule. This type of CAR T-cell therapy is still in the early stages of development and has the potential to improve the safety and effectiveness of CAR T-cell therapy.

End User Outlook

The end-user segment of the global CAR T-cell therapy market refers to the different types of healthcare facilities and organizations that use and administer CAR T-cell therapy. Here is an analysis of the end-user segment of the market:

Research institutes are important end users of CAR T-cell therapy because they are involved in the development and testing of new CAR T-cell therapies. Research institutes also provide a platform for preclinical studies, which are essential in advancing the development of CAR T-cell therapies.

Regional Analysis

The global CAR T-cell therapy market is expected to grow significantly in the coming years, and the growth is expected to vary across different regions. Here is a regional analysis of the CAR T-cell therapy market:

North America is currently the largest market for CAR T-cell therapy, and it is expected to continue to dominate the market in the coming years. The high prevalence of cancer and the presence of major biotechnology and pharmaceutical companies in the region are the major factors driving the growth of the market.

Europe is the second-largest market for CAR T-cell therapy, and it is expected to grow significantly in the coming years. The growing adoption of CAR T-cell therapy, favorable reimbursement policies, and the presence of major biotechnology and pharmaceutical companies are the major factors driving the growth of the market.

The Global CAR T-cell Therapy Market has been segmented into:

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Others

By End User

• Hospitals
• Cancer Treatment Centers

By Drug Type

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

By Region

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Market Players 

The global CAR T-cell therapy market is highly competitive and fragmented, with numerous players vying for market share. Some of the key companies in the market are:

• Autolus Therapeutics
• Bluebird bio, Inc.
• Bristol-Myers Squibb
• Caribou Biosciences, Inc.
• Cartesian Therapeutics, Inc.
• Celgene Corporation
• Cellectis
• Celyad Oncology
• Gilead Sciences, Inc. (Kite Pharma Inc.) 
• Intellia Therapeutics
• Juno Therapeutics, Inc.
• Merck & Co., Inc.
• Miltenyi Biotech
• Novartis AG
• Pfizer, Inc.
• Sorrento Therapeutics, Inc.

Novartis was the first company to receive FDA approval for a CAR T-cell therapy, Kymriah, and is a leading player in the market. Novartis is also developing other CAR T-cell therapies for a variety of cancers, including multiple myeloma.

Gilead Sciences acquired Kite Pharma, which developed the CAR T-cell therapy Yescarta, and is now a major player in the CAR T-cell therapy market. Gilead Sciences is also developing other CAR T-cell therapies for various types of cancer.

Sorrento Therapeutics is developing CAR T-cell therapies for a variety of cancers, including solid tumors. Sorrento Therapeutics is also developing other immunotherapies and diagnostic tests.

Mustang Bio is developing CAR T-cell therapies for various types of cancer, including glioblastoma and leukemia. Mustang Bio is also developing other gene therapies for rare diseases.

Strategic Developments

The global CAR T-cell therapy market has seen several strategic developments in the form of mergers, acquisitions, and investments. Here are some examples:

Novartis acquired AveXis, a gene therapy company, in 2018 for $8.7 billion. This acquisition gave Novartis access to a promising gene therapy pipeline, including treatments for spinal muscular atrophy and Rett syndrome.

Gilead Sciences acquired Kite Pharma, a CAR T-cell therapy company, in 2017 for $12 billion. This acquisition gave Gilead Sciences access to Yescarta, a CAR T-cell therapy for lymphoma, as well as Kite Pharma's pipeline of CAR T-cell therapies for other types of cancer.

Sorrento Therapeutics received a $30 million investment from Fortress Biotech in 2019 to support the development of its CAR T-cell therapies for solid tumors. Sorrento Therapeutics is also partnering with Celularity to develop CAR T-cell therapies for COVID-19.

Mustang Bio received a $20 million investment from Fortress Biotech in 2019 to support the development of its CAR T-cell therapies for leukemia and glioblastoma.